ARCHIVES

Interim NSABP Leaders Will Not Nominate Chairman, Citing Exec. Committee “Bias”

This article is from The Cancer Letter archive.

Vol. 20 No. 34 | September 9, 1994

Download PDF Visit The Full Archive

Related Articles

NeoRx Suspends Accrual, Treatment In Phase III trial Using STR For Myeloma.

December 1, 2000

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013

Dana-Farber Opens Imaging Center

May 8, 2009

Cancer Letter Adds Associate Editor

July 19, 1985

ACCC Unit Reaches Consensus On Outline of HOP; Each Member Would Relate To Center Or Cooperative Group

September 11, 1981

NCAB Votes No To Funding Diet FIT, Citing NCI Resources

December 8, 1989